Evidence map›Paper›PMID 42360649›Full record

ReviewMedical oncology (Northwood, London, England)2026

Chromatin chronicles: Unlocking the therapeutic potential of histone modifiers in hepatocellular carcinoma.

Muhammad Sulaiman, Ziyi Chen, Yimin Nie, Umm E Hani, Faisal Raza, Julius Mulumba, Zhibo Zhang, Mei Yang, Shengtao Yuan, Chunyu Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Muhammad Sulaiman *New Drug Screening and Pharmacodynamics Evaluation Center National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing, 210009, China.
Ziyi Chen *New Drug Screening and Pharmacodynamics Evaluation Center National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing, 210009, China.
Yimin NieCollege of Life Science, Jilin Agriculture University, Changchun, 130118, China.
Umm E HaniDepartment of Pharmaceutical Engineering School of Engineering, China Pharmaceutical University, 211198, Nanjing, People's Republic of China.
Faisal RazaSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
Julius MulumbaSchool of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Zhibo ZhangNew Drug Screening and Pharmacodynamics Evaluation Center National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing, 210009, China.
Mei YangNew Drug Screening and Pharmacodynamics Evaluation Center National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing, 210009, China.
Shengtao YuanNew Drug Screening and Pharmacodynamics Evaluation Center National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing, 210009, China. yuanst1967@163.com.
Chunyu SunCollege of Life Science, Jilin Agriculture University, Changchun, 130118, China. cysun@jlau.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) represents the primary liver cancer among adults with diverse tissue appearance, high disease severity, and negative treatment expectancy. The molecular heterogeneity, extensive invasion, and propensity for relapse of HCC present a substantial challenge for oncologists. Hepatoma cells display deregulated genomic pathways interacting with epigenetic modifications. Epigenetic changes are crucial in HCC research, serving as potential biomarkers for tumor classification, prognosis, and drug targeting. Histone PTMs and chromatin regulation control gene expression during malignant transformation and tumor progression. The development of HCC is influenced by the alteration in the expression of genes that encode acetyltransferases and deacetylases (KAT6A, SIRT2, SIRT7, HDAC4, 6, 9) and lysine and arginine methyltransferases (G9a, SUV39H1, and SETDB1). Furthermore, HCC cell lines exhibit an upregulation of proteins from the sumoylation pathway, such as E1 (SAE1), E2 (Ubc9) components, and a SUMO-specific protease (SENP1) and TGM2 from serotonylation respectively. The latest generation of HDAC inhibitors, protein arginine methyltransferase (PRMT) inhibitors, and bromodomain inhibitors are being studied in preclinical and clinical research for HCC treatment. The article provides an extensive breakdown of contemporary HCC epigenetic research focusing on histone modifications while exploring epigenetic therapy as an available treatment approach for HCC. This review is a summary on the existing knowledge on the various epigenetic mechanisms that shape HCC biology with a special focus on histone-modifying enzymes, newly identified epigenetic regulators, and their therapeutic potential.

Indexed as

Carcinoma, HepatocellularChromatinHistonesLiver NeoplasmsEpigenesis, GeneticGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansChromatinHistone Deacetylase InhibitorsHistonesEpigenetic therapyHepatocellular carcinomaHepatocellular carcinoma therapyHistone modificationsHistone target therapy

Identifiers

PMID42360649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.